These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31445807)

  • 1. The accuracy of a point of care measurement of activated partial thromboplastin time in intensive care patients.
    Karigowda L; Deshpande K; Jones S; Miller J
    Pathology; 2019 Oct; 51(6):628-633. PubMed ID: 31445807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point of care and central laboratory determinations of the aPTT are not interchangeable in surgical intensive care patients.
    Ferring M; Reber G; de Moerloose P; Merlani P; Diby M; Ricou B
    Can J Anaesth; 2001 Dec; 48(11):1155-60. PubMed ID: 11744594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bedside coagulometry during intravenous heparin therapy after coronary angioplasty.
    Schroeder AP; Knudsen LL; Husted SE; Knudsen L; Ingerslev J
    J Thromb Thrombolysis; 2001 Oct; 12(2):157-63. PubMed ID: 11729367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
    Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
    Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a bedside device to assess the activated partial thromboplastin time for heparin monitoring in infants.
    Klein RH; van der Vorst MM; de Wilde RB; Hogenbirk K; de Kam ML; Burggraaf J
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):327-31. PubMed ID: 23337708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limits of agreement between measures obtained from standard laboratory and the point-of-care device Hemochron Signature Elite(R) during acute haemorrhage.
    Gauss T; Hamada S; Jurcisin I; Dahmani S; Boudaoud L; Mantz J; Paugam-Burtz C
    Br J Anaesth; 2014 Mar; 112(3):514-20. PubMed ID: 24335551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-blood Point-of-Care Activated Partial Thromboplastin Time Ratio (APR) is not Accurate Enough to Monitor Heparin Therapy in Patients with Severe Respiratory Failure Secondary to SARS-Cov-2 Infection Supported with Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO).
    Aston D; Besser M; Goddard B; Maggs N; Ahmed H; Falter F
    Clin Appl Thromb Hemost; 2022; 28():10760296221148162. PubMed ID: 36572963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point-of-care (POC) measurement of coagulation after cardiac surgery.
    Boldt J; Walz G; Triem J; Suttner S; Kumle B
    Intensive Care Med; 1998 Nov; 24(11):1187-93. PubMed ID: 9876982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators.
    Becker RC; Ball SP; Eisenberg P; Borzak S; Held AC; Spencer F; Voyce SJ; Jesse R; Hendel R; Ma Y; Hurley T; Hebert J
    Am Heart J; 1999 Jan; 137(1):59-71. PubMed ID: 9878937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of five point-of-care prothrombin and activated partial thromboplastin time devices based on age of blood sample.
    Searles B; Nasrallah F; Graham S; Lajara RB
    J Extra Corpor Technol; 2002 Sep; 34(3):178-81. PubMed ID: 12395962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Point-of-care measurement of activated clotting time for cardiac surgery as measured by the Hemochron signature elite and the Abbott i-STAT: agreement, concordance, and clinical reliability.
    Dirkmann D; Nagy E; Britten MW; Peters J
    BMC Anesthesiol; 2019 Sep; 19(1):174. PubMed ID: 31492108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring.
    Taylor CT; Petros WP; Ortel TL
    Pharmacotherapy; 1999 Apr; 19(4):383-7. PubMed ID: 10212007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring the effects of heparin: evaluation of a new portable device.
    Cavanagh SP; Haine L; Ammori B; Tate G; Braithwaite P; Gough MJ; Homer-Vanniasinkam S
    Cardiovasc Surg; 1998 Oct; 6(5):496-9. PubMed ID: 9794270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of the activated clotting time for monitoring heparin therapy in critically ill patients.
    De Waele JJ; Van Cauwenberghe S; Hoste E; Benoit D; Colardyn F
    Intensive Care Med; 2003 Feb; 29(2):325-8. PubMed ID: 12594595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation.
    Teng Y; Yan S; Liu G; Lou S; Zhang Y; Ji B
    Front Med (Lausanne); 2022; 9():931863. PubMed ID: 35847800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the activated partial thromboplastin time for heparin monitoring.
    Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
    Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing methods of establishing the aPTT therapeutic range of heparin.
    Liepman CI; Koerber JM; Mattson JC; Westley SJ; Smythe MA
    Ann Pharmacother; 2003 Jun; 37(6):794-8. PubMed ID: 12773063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Point of care measurement of lepirudin and heparin anticoagulation during systemic inflammation.
    Homoncik M; Pernerstorfer T; Reiter R; Knechtelsdorfer M; Quehenberger P; Jilma B
    Thromb Res; 2002 Oct; 108(1):91-5. PubMed ID: 12586138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of point-of-care activated partial thromboplastin time testing by comparison to laboratory-based assay for control of intravenous heparin.
    Douglas AD; Jefferis J; Sharma R; Parker R; Handa A; Chantler J
    Angiology; 2009; 60(3):358-61. PubMed ID: 19398428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between activated clotting time and activated partial thromboplastin times.
    Smythe MA; Koerber JM; Nowak SN; Mattson JC; Begle RL; Westley SJ; Balasubramaniam M
    Ann Pharmacother; 2002 Jan; 36(1):7-11. PubMed ID: 11816262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.